Alkermes plc $ALKS is Commodore Capital LP’s 7th Largest Position

Commodore Capital LP grew its holdings in Alkermes plc (NASDAQ:ALKS) by 26.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,096,754 shares of the company’s stock after acquiring an additional 646,754 shares during the period. Alkermes comprises approximately 4.5% of Commodore Capital LP’s portfolio, making the stock its 7th largest position. Commodore Capital LP owned 1.88% of Alkermes worth $92,903,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Assetmark Inc. boosted its holdings in Alkermes by 933.8% in the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 747 shares during the period. Johnson Financial Group Inc. purchased a new stake in Alkermes during the 3rd quarter worth about $31,000. Hantz Financial Services Inc. raised its position in Alkermes by 395.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock valued at $37,000 after purchasing an additional 989 shares in the last quarter. Osaic Holdings Inc. raised its position in Alkermes by 56.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock valued at $56,000 after purchasing an additional 701 shares in the last quarter. Finally, Bessemer Group Inc. boosted its stake in shares of Alkermes by 163.3% in the 3rd quarter. Bessemer Group Inc. now owns 2,222 shares of the company’s stock valued at $67,000 after buying an additional 1,378 shares during the period. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ALKS has been the subject of a number of analyst reports. Wall Street Zen downgraded Alkermes from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Wolfe Research assumed coverage on shares of Alkermes in a research note on Monday, February 23rd. They issued an “outperform” rating and a $45.00 price target for the company. Wells Fargo & Company boosted their price target on shares of Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Truist Financial increased their price objective on shares of Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Zacks Research cut shares of Alkermes from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Alkermes has an average rating of “Moderate Buy” and an average target price of $44.07.

Alkermes Stock Up 0.4%

Shares of ALKS opened at $27.76 on Friday. The company has a market capitalization of $4.63 billion, a price-to-earnings ratio of 19.41, a price-to-earnings-growth ratio of 6.92 and a beta of 0.53. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $36.32. The stock has a 50 day moving average price of $31.58 and a 200 day moving average price of $30.19.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The company had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The firm’s revenue for the quarter was down 10.6% compared to the same quarter last year. During the same period in the previous year, the business posted $1.05 EPS. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, equities analysts anticipate that Alkermes plc will post 1.31 EPS for the current fiscal year.

Insider Activity at Alkermes

In related news, Director Shane Cooke sold 61,200 shares of Alkermes stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the sale, the director directly owned 103,744 shares in the company, valued at $3,586,430.08. This trade represents a 37.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Christian Todd Nichols sold 6,000 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $30.00, for a total transaction of $180,000.00. Following the completion of the sale, the senior vice president directly owned 109,769 shares of the company’s stock, valued at approximately $3,293,070. This trade represents a 5.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 157,434 shares of company stock valued at $5,305,794 over the last quarter. 4.40% of the stock is owned by insiders.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.